|Awarded On||November 19, 2015|
|Title||Engineering T cells to ensure specificity for tumor cells and their environment|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Malcolm K Brenner|
|Cancer Sites||Leukemia, Lymphoma, Myeloma|
T lymphocytes are among the most important cells of the immune system. Cancer treatments based on these cells can have dramatic therapeutic activity against some cancers, but in most patients, these therapies are not yet fully effective. Most notably, dangerous side effects can occur if the T cells are activated too strongly and begin to release harmful substances or if they attack normal organs instead of focusing only on the tumors. For these therapies, T cells from the patient’s blood are processed in the laboratory to increase their ability to attack cancer cells and then returned to the patient. We have previously developed a method to safely attack a molecule present on many different ...